media – Page 408 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Link found between late eating and higher consumption of ultra-processed foods

Bonaccio M, Ruggiero E, Di Castelnuovo A, et al. Association between Late-Eating Pattern and Higher Consumption of Ultra-Processed Food among Italian Adults: Findings from the INHES Study. Nutrients, 2023, DOI: 10.3390/nu15061497, https://www.mdpi.com/2072-6643/15/6/1497 In a recent study published in the journal Nutrients, researchers in Italy examined the associations between meal timing and food processing. Unhealthy diets are risk factors for obesity and related disorders. As such, strategies to tackle obesity have been focused on food compositions, resulting in recommendations to lower sugar, salt, and fat intake, with a concomitant increase in fiber, vitamin, and mineral intake. Much research has been centered on meal timing, with population studies implicating late eating in obesity and nutrition-related non-communicable diseases. Nonetheless, no study has investigated the relationship between meal timing and processed foods. About the study In the present study, researchers evaluated whether meal timing is associated with foods with different ...
- Source: drugdu
- 133
- March 28, 2023
Patients losing out amid slump in NHS clinical trials, warn top clinicians UK falls from fourth to 10th place in phase III trials amid ‘ossified’ bureaucracy and stretched health service

The state of clinical trials in the NHS is “much worse than it has been in years” with patients losing access to cutting-edge cancer and dementia treatments, one of the UK’s most senior clinicians has warned. Sir John Bell, the regius professor of medicine at the University of Oxford and a government life sciences adviser, said the UK’s approach needed “a full overhaul, top to bottom” to prevent a collapse in the number of clinical trials being conducted in the NHS. “I don’t think there’s any doubt that companies are choosing not to evaluate their drugs in the UK,” he said. “The risks [to patients] are much bigger than have been alluded to.” The intervention comes after the government launched an independent review led by the former health minister James O’Shaughnessy into why the NHS had seen a 44% drop in participants recruited to commercial clinical trials in the past five years. The UK is rapidly ...
- Source: drugdu
- 130
- March 28, 2023
GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate There are currently no licensed vaccines offering simultaneous protection against all five serogroups

GSK has reported positive top-line results from a phase 3 study of its five-in-one meningococcal vaccine candidate, MenABCWY, in healthy individuals aged ten to 25 years. Invasive meningococcal disease (IMD) is an uncommon but serious illness that can cause life-threatening complications or even death, with the highest incidence occurring in children and adolescents. Five Neisseria meningitides serogroups – A, B, C, W, and Y – account for nearly all IMD cases, but there are currently no licensed vaccines that offer simultaneous protection against all of them. In the US, two separate vaccines needing four injections are required to protect against all five serogroups. This regimen, together with low awareness of the disease, can lead to poor immunisation rates, with an estimated coverage of only 31% of adolescents in the US. It is hoped that GSK’s MenABCWY, which combines the antigenic components of its licensed Bexsero (MenB) and Menveo (MenACWY) meningococcal ...
- Source: drugdu
- 157
- March 27, 2023
new research New data suggests ‘huge overuse of antibiotics’

Most patients who are admitted to hospitals with acute viral infections are given antibiotics by their doctors or health care providers as a precaution against bacterial co-infection. Yet new research suggests this practice may not improve their survival rates. Researchers investigated the impact of antibiotic use on survival in more than 2,100 patients in a hospital in Norway between the years 2017 and 2021, Reuters reported. ‘SILENT PANDEMIC’ WARNING FROM WHO: BACTERIA KILLING TOO MANY PEOPLE DUE TO ANTIMICROBIAL RESISTANCE The researchers found that giving antibiotics to people with common respiratory infections was unlikely to lower the risk of death within 30 days. At the height of the COVID-19 pandemic, antibiotics were prescribed for around 70% of COVID-19 patients in some countries, Reuters also said. This potentially has contributed to the scourge of antibiotic-resistant pathogens known as superbugs. The new data has not been published in a medical journal ...
- Source: drugdu
- 126
- March 27, 2023
Users of recalled eye drops describe permanent vision problems after infections

Renee Martray of South Carolina has severe and permanent corneal scarring resulting in vision loss. She says it’s like trying to peer through eyeglasses that have been dipped in oil. Nancy Montz of Ohio developed a corneal ulcer, spent three weeks in the hospital and lost vision in her left eye. Carla Oliva of Florida developed a severe eye infection and, when treatment failed, had to have her right eye removed. She’s now legally blind. The women said their problems began after they used EzriCare Artificial Tears, which is part of a US Centers for Disease Control and Prevention and US Food and Drug Administration investigation into a multistate outbreak of a rare strain of bacteria. EzriCare said in a statement last month that when it learned of the investigation January 20, it was not aware of any testing that definitively linked the outbreak to its product. “Nonetheless, we immediately ...
- Source: drugdu
- 144
- March 27, 2023
FT

Pfizer and European Commission officials have waded through months of pushback over a large, controversial COVID-19 vaccine supply deal in Europe. They’ve now reportedly hashed out a new supply agreement—but there’s a catch. Under the terms of a revised deal, Pfizer agreed to extend the European supply contract from 2023 out to 2026, the Financial Times reports based on two people with knowledge of the talks. Given the drop in vaccine use, Pfizer also agreed to cut the total number of doses to be supplied by 40%, but the company is also pushing for payment for the doses that will never be manufactured, according to the publication. Pfizer and the European Commission (EC) inked their large vaccine supply deal in May 2021. The agreement covered 900 million vaccine doses for delivery split between 2022 and 2023, with the option for the EC to order another 900 million doses in the future. In December 2021, European officials exercised part of ...
- Source: drugdu
- 519
- March 24, 2023
England’s NICE signs off on PTC Therapeutics’ $3.7M gene therapy for ultra-rare disease

The National Institute for Health and Care Excellence (NICE) has recommended the therapy to treat patients with aromatic L-amino acid decarboxylase (AADC) deficiency who are 18 months and older. PTC has inked a confidential discount access scheme to make Upstaza available to the National Health Service (NHS), NICE says. The drug carries a list price of 3 million pounds sterling (around $3.71 million) per 0.5-mL infusion solution before the confidential discount. AADC deficiency is so rare that it affects an estimated 10 children in the U.K., only a few of whom could be eligible for the treatment. The disease causes a wide range of severe symptoms, but around 80% of patients have a severe form that leaves them fully dependent on caregivers and unable to meet normal developmental milestones. Due to the rarity of this condition, there isn’t much research on the expected life span of a person with AADC deficiency. It’s estimated that most ...
- Source: drugdu
- 146
- March 24, 2023
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon

On March 21, Selecta Biosciences and Sobi announced positive pivotal results from two phase III studies (DISSOLVE I and DISSOLVE II). These two placebo-controlled, randomized clinical trials were designed to evaluate the safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout. Gout is an autoinflammatory disease in which patients experience severe pain and debilitating inflammatory arthritis due to deposits of pro-inflammatory sodium urate (MSU) crystals. Patients with chronic refractory gout often have a high tissue MSU burden, which can lead to frequent gout attacks and chronic arthritis. Gout is the most common inflammatory arthritic disease in the United States. SEL-212 has the potential to reduce serum uric acid and MSU deposition in patients with chronic refractory gout. Recombinant uricase is highly immunogenic in the human body. Through Selecta’s proprietary ImmTOR platform, SEL-212 has the potential to alleviate the formation of anti-drug antibodies, ...
- Source: drugdu
- 159
- March 24, 2023
India cancels licence of drug maker linked to child deaths in Uzbekistan

India has cancelled the manufacturing licence of a firm whose cough syrups have been linked to 18 child deaths in Uzbekistan. The WHO in January had warned against the use of two cough syrups made by Marion Biotech, saying they were substandard. Marion Biotech denies the allegations. After the deaths were reported in Uzbekistan, India’s health ministry had suspended production at the company. On Wednesday, authorities in Uttar Pradesh state – where Marion Biotech is based – said they were now “permanently” cancelling the company’s licence. “The firm based in Noida city cannot carry out any manufacturing now,” drug inspector Vaibhav Babbar told the Hindustan Times newspaper. The BBC has reached out to state authorities for a statement. Marion Biotech has not responded to BBC’s request for comment. India is the world’s largest exporter of generic drugs, meeting much of the medical ...
- Source: drugdu
- 150
- March 24, 2023
Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance is becoming more prevalent, affecting 15.5% to 46.5% of the world’s population Novo Nordisk and Dewpoint Therapeutics have entered into a research and development partnership aimed at identifying drug candidates to treat insulin resistance and diabetic complications. A key driver of type 2 diabetes and metabolic syndrome, insulin resistance occurs when the body has an impaired response to insulin, resulting in elevated levels of glucose in the blood. The condition is rising in prevalence globally, affecting 15.5% to 46.5% of the world’s population. The collaboration will see the partners use Dewpoint’s discovery and AI technology platform to identify modulators of biomolecular condensates – membraneless organelles comprising proteins and RNA – that may be involved in insulin resistance and insulin sensitivity. The dysregulation of these condensates has been observed in many diseases, including diabetes, which is why Dewpoint believes that using its platform to develop ...
- Source: drugdu
- 135
- March 24, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.